Since 2020, Eli Lilly's stock has skyrocketed by 568.82%, reflecting incredible growth that has propelled its market capitalization from $100 billion to $740 billion.
Eli Lilly's recent stock increase is attributed not just to past growth, but to projected revenues and a strategic focus on expanding its therapeutic offerings.
Analyst ratings are optimistic, with Deutsche Bank maintaining a 'Buy' recommendation and setting a target price of $1,025, driven by the resolution of drug supply shortages.
The establishment of the Lilly Medicine Foundry, with a $4.5 billion investment, signifies Eli Lilly’s commitment to innovation in drug development and advanced manufacturing.
Collection
[
|
...
]